Sorafenib Tosylate CAS 475207-59-1 Maʻemaʻe ≥99.0% (HPLC) API Factory ʻO ke ʻano kiʻekiʻe.
Hāʻawi Kūʻai ʻo Sorafenib Tosylate a me nā mea waena e pili ana:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
| Inoa Kimia | ʻO Sorafenib Tosylate |
| Nā huaʻōlelo like | Nexavar;4-[4-[3-[4-Chloro-3-(Trifluoromethyl)phenyl]ureido]phenoxy]-N-Methylpicolinamide 4-Methylbenzenesulfonate;4-[4-[[4-Chloro-3-(Trifluoromethyl)phenyl]carbamamido]phenoxy]-N-Methyl-2-Pyridinecarboxamide 4-Methylbenzenesulfonate;BAY 43-9006 Tosylate |
| Helu CAS | 475207-59-1 |
| Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
| ʻĀpana Molekala | C21H16ClF3N4O3.C7H8O3S |
| Kaumaha Molecular | 637.03 |
| Lae hehee | 225.0 a 230.0 ℃ |
| Pilikino | Paʻi Lewa, Paʻa Wela |
| Ka hikiwawe | Hiki ke hoʻoheheʻe ʻia i loko o ka wai (<1 mg/ml) ma 25 ℃, DMSO (127 mg/ml) ma 25 ℃, a me Ethanol (<1 mg/ml) ma 25 ℃ |
| Nā Kūlana Hoʻouna | Wahi Hauʻoli a maloʻo (2 ~ 8 ℃), pale mai ka mālamalama |
| COA & MSDS | Loaʻa |
| Ola Pahu | 2 makahiki inā mālama pono ʻia |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī | Nā hualoaʻa |
| Ka nana aku | Melemele māmā a i ʻole ka pauda keʻokeʻo | Hoʻokō |
| Maʻemaʻe / Kaʻina Hanana | ≥99.0% (HPLC) | 99.8% |
| Lae hehee | 225.0~230.0 ℃ | Hoʻokō |
| Nā Metala Kaumaha | ≤10ppm | <10ppm |
| Nalo ma ka maloo | ≤0.50% | 0.12% |
| Koena ma ka Ignition | ≤0.20% | 0.10% |
| ʻO kēlā me kēia haumia hoʻokahi | ≤0.50% | Hoʻokō |
| Huina paumaele | ≤0.50% | Hoʻokō |
| NMR Spectrum | Kūlike i ka hoʻolālā | Hoʻokō |
| Kūlana hoʻāʻo | Kūlana ʻoihana | Hoʻokō |
| Hoʻohana | Sorafenib Tosylate (CAS: 475207-59-1) i ka mālama ʻana iā RCC & HCC | |
Pūʻolo:ʻO ka ʻōmole, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o kahi pahu paʻa.E kūʻai i loko o kahi hale kūʻai maloʻo, maloʻo (2 ~ 8 ℃) a me ka ventilated maikaʻi mai nā mea like ʻole.E pale i ka malamalama a me ka wai.
Hoʻouna:Hāʻawi i ka honua ma ka lewa, e FedEx / DHL Express.Hāʻawi wikiwiki a hilinaʻi hoʻi.
Nā Code Risk 36/37/38 - He mea hoʻonāukiuki i nā maka, ʻōnaehana hanu a me ka ʻili.
ʻO ka wehewehe palekana S28 - Ma hope o ka hoʻopili ʻana me ka ʻili, holoi koke me ka nui o ke kopa.
S26 - Inā pili me nā maka, e holoi koke me ka wai nui a e ʻimi i ka ʻōlelo aʻo kino.
ʻO Sorafenib Tosylate (CAS: 475207-59-1) kahi ʻano hou o ka lāʻau antitumor multi-target, i hoʻomohala ʻia e ka German Bayer Pharmaceuticals, a hōʻike i ka hana antitumor expansive i nā hoʻokolohua holoholona preclinical.Loaʻa ka Sorafenib i nā papa 200-mg no ka hoʻokele waha a hoʻohana ʻia i ka mālama ʻana o RCC a me HCC.Hiki i ka Sorafenib Tosylate ke hoʻopili i nā pūnaewele tumo a me nā kīʻaha koko koko.Loaʻa iā ia ka hopena antitumor pālua: hiki iā ia ke ālai i nā ala transduction hōʻailona cell i hoʻopili ʻia e RAF/MEK/ERK e hoʻopaʻa pololei i ka ulu ʻana o ka cell tumor, ʻoiai ke kāohi pū nei i ka VEGF a me nā platelet derived growth factor (PDGF) i mea e pale ai i ke kūkulu ʻana i ke koko koko hou. nā moku, no laila ke keʻakeʻa nei i ka ulu ʻana o nā cell tumor.
ʻO Sorafenib Tosylate, ka inoa kālepa Nexavar, ua hoʻomohala mua ʻia e Bayer Pharmaceuticals ma Kelemānia.ʻO Sorafenib Tosylate kahi mea hoʻopaneʻe multi-kinase hiki ke hoʻohana ʻia e mālama i nā maʻi e like me ke kanesa.I Kekemapa 2005, ua ʻae ʻia e ka US FDA ma ke ʻano he lāʻau lapaʻau mua no ka mālama ʻana i ka maʻi maʻi renal holomua.I ʻAukake 2009, ua hoʻopaʻa inoa ʻia ma Kina me ka ʻae ʻia e ka State Food and Drug Administration.
ʻO Sorafenib Tosylate nā tyrosine kinases (VEGFR a me PDGFR) a me RAF / MEK / ERK cascade inhibitors, e hana like ana ma Raf-1, wtBRAF a me V599EBRAF, me IC50 o 6 nM, 22 nM a me 38 nM.
Hiki i ka Sorafenib Tosylate ke kāohi i nā ʻano kinase e noho nei ma ke kelepona a me ka ʻili o ka cell, e komo pū me RAF kinase, vascular endothelial growth factor receptor-2 (VEGFR-2), vascular endothelial growth factor receptor-3 (VEGFR-3), platelet -i loaʻa i ka mea hoʻonui mea hoʻokipa-β (PDGFR-β), KIT a me FLT-3.Hiki ke ʻike ʻia he mau hopena anti-tumor ʻelua ka sorafenib toluenesulfonate.Ma kekahiʻaoʻao, hiki iā ia ke pale pololei i ka uluʻana o ka maʻi maʻi ma ke kāohiʻana i ke ala hōʻailona RAF / MEK / ERK;ma kekahi ʻaoʻao, hiki iā ia ke kāohi i ka VEGFR a me PDGFR.A pale i ka hoʻokumu ʻana o ka neovascularization tumor, indirectly inhibit the growth of tumor cells.ʻO Sorafenib Tosylate ka lāʻau lapaʻau maikaʻi loa no ka mālama ʻana i ka maʻi maʻi ate holomua e ka hoʻokele ʻōnaehana, a e lilo paha ia i lāʻau maʻamau hou no ka mālama ʻana i kēia maʻi.
Ua hōʻike ʻo Sorafenib Tosylate i kēlā me kēia lā o ka hoʻokele waha o ke kanaka maʻi maʻi maʻi hoʻololi holoholona i ka nui o ka hana anti-tumor, e like me ka maʻi maʻi colon, non-liʻiliʻi cell carcinoma, umauma maʻi maʻi, melanoma, pancreatic cancer, leukemia a me ka maʻi ovarian a me ka ʻiole renal cell carcinoma. kumu hoʻohālike, RENCA model.
